Glucosamine Joint Mobility Randomized Trial: What the Evidence Says

Quick Answer

Glucosamine Joint Mobility Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Another worldwide study found that the prevalence was almost 29.5% and that women are more likely to be affected than men. [Gazali Mohammad (2026); evidence level 3]
• Psychological interventions, such as cognitive-behavioral therapy, are gaining popularity for their effectiveness when used in conjunction with biomedical treatments, indicating that a holistic approach can produce substantial result. [Gazali Mohammad (2026); evidence level 3]
• It causes chronic pain, reduced mobility, and disability, affecting 607 million individuals worldwide, with nearly 46.6 million new cases annually. [Muacevic Alexander (2026); evidence level 4]
• HLA-DRB1 HLA-DQB1 Genetic polymorphisms in sterol regulatory element-binding protein 2 (rs2228314), interleukin-6 (rs1800795), and resistin (RETN) in Indian and Pakistani cohorts and growth differentiation factor 5 (rs143383),, andin Thai populations are linked to OA risk. [Muacevic Alexander (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For glucosamine joint mobility randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Gazali Mohammad (2026). Diagnosis-based pathways for conservative and minimally invasive management of temporomandibular disorders: a scoping review. DOI: 10.22514/jofph.2026.034. PMCID: PMC13223916. PMID: 42220286. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13223916/
• Muacevic Alexander (2026). Evidence-Based Use of Undenatured Type II Collagen in the Management of Osteoarthritis in the Indian Subcontinent and Southeast Asia: A Narrative Review and an Expert Opinion. DOI: 10.7759/cureus.109411. PMCID: PMC13283519. PMID: 42333321. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13283519/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.